All In Biotech

Free tool

FAERS Monitor: Libtayo

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761097 or its brand name (Libtayo, Cemiplimab-Rwlc). Reports on generic versions are filed under their own applications.

Reports

2,083

Serious

1,728

83% of reports

Hospitalization

608

Death reported

438

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death176
  • disease progression155
  • off label use107
  • fatigue88
  • rash86
  • dyspnoea65
  • pyrexia64
  • pruritus53
  • interstitial lung disease50
  • myocarditis50
  • asthenia47
  • drug ineffective47
  • diarrhoea46
  • nausea45
  • pneumonia41

Reports by year received

View as table
YearReports
20187
2019138
2020105
2021204
2022292
2023258
2024345
2025435
2026299

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,076 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
myocarditisSignal5044.233.62,062
disease progressionSignal15513.211.41,750
interstitial lung diseaseSignal5010.47.9418
deathSignal1762.11.899
rash862.01.642
pyrexia641.91.525
pruritus531.41.16
pneumonia411.30.92
asthenia471.31.02
off label use1071.21.05
dyspnoea651.20.91
fatigue881.10.91
diarrhoea460.70.55
nausea450.60.414
drug ineffective470.40.356

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.